BioSpace News Archive

Dr. Reddy’s Laboratories Ltd. announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL_RI, for filing in highly regulated markets such as the United States, Europe and other regions.

Disc Medicine, Inc. (NASDAQ:IRON) announced today that is has entered into an agreement with Mabwell Therapeutics to obtain an exclusive license to a portfolio of monoclonal antibodies targeting TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) including the phase 1-ready drug candidate MWTX-003.

Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for Mindset’s patent application number 17/833,341, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”

SK bioscience announced that Richard Kensinger, PhD, former Director and Head of Drug Substance Process Development in Sanofi Pasteur and former Executive Director of Process Development and Protein Sciences at Affinivax Inc. has joined in ‘SK bioscience USA Inc.’ as Vice President of R&D Project Management.

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has taken the Zero Health Gaps Pledge at the World Economic Forum in Davos, Switzerland.

Vivos Therapeutics, Inc. today announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) informing Vivos it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2).

Umbra Applied Technologies Group, Inc. announce that its subsidiary, Ossifix Orthopedics has begun a comparative study with doctors across six different sites.

Insmed Incorporated today announced the granting of inducement awards to 10 new employees.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed the closing of our previously announced definitive agreement with Akeso Inc.